Affordable Access

The role of biologics in treatment of ANCA-associated vasculitis

Publication Date
  • Medicine


The vast majority of patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV) who receive conventional treatment with glucocorticoids and cyclophosphamide experience frequent relapses and treatment-related side-effects. Increasing knowledge of the pathogenesis of AAV has permitted the development of targeted therapies against tumour necrosis factor (TNF)-a and T and B lymphocytes. Therapy with TNF-a blocking drugs has so far proved disappointing, and this approach is not recommended. B cell depletion using rituximab is effective for remission induction, especially in refractory patients. The long-term side-effects and the best method of using rituximab to maintain remission are still to be determined.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times